June 27, 2017 - Earlier this year, we focused one of our client alerts on a new Guidance issued by the Food and Drug Administration (FDA) concerning certain prescription requirements for compounding human drug products under section 503A of the Federal Food, Drug, and Cosmetic Act. See "FDA Issues Guidance on Prescription Requirement for Compounded [...]
January 20, 2017 — The Food and Drug Administration (FDA) recently issued a Guidance concerning certain prescription requirements for compounding human drug products under section 503A of the Federal Food, Drug, and Cosmetic Act (the “Act”). The Guidance does not set forth any legal responsibilities. Rather, the FDA describes how the agency plans to implement and [...]
Former Heritage Pharmaceuticals Execs Admit to Price Fixing Government Continues to Focus on Generic Drug Industry Since early December of 2016, we've been tracking federal price fixing charges brought against two ex-pharmaceutical executives – Jeffrey Glazer and Jason Malek – both formerly of Heritage Pharmaceuticals. On January 9, 2017, the two entered guilty pleas in [...]
